Anzeige
Mehr »
Login
Donnerstag, 10.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Schickt KI Kupfer in einen Superzyklus? Warum diese Aktie mit steigender Kupfernachfrage explodieren könnte…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0Q67J | ISIN: US5628031065 | Ticker-Symbol:
NASDAQ
09.10.24
15:30 Uhr
5,410 US-Dollar
0,000
0,00 %
1-Jahres-Chart
MANHATTAN BRIDGE CAPITAL INC Chart 1 Jahr
5-Tage-Chart
MANHATTAN BRIDGE CAPITAL INC 5-Tage-Chart
GlobeNewswire (Europe)
263 Leser
Artikel bewerten:
(1)

Manhattan Bridge Capital, Inc. Reports Results for 2023

GREAT NECK, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the "Company") announced today that net income for the year ended December 31, 2023 was approximately $5,476,000, or $0.48 per share (based on approximately 11.5 million weighted-average outstanding common shares), versus approximately $5,212,000, or $0.45 per share (based on approximately 11.5 million weighted-average outstanding common shares) for the year ended December 31, 2022, an increase of $264,000, or 5.1%. This increase is primarily attributable to an increase in interest income from loans, partially offset by increases in interest expense and in general and administrative expenses.

Total revenue for the year ended December 31, 2023 was approximately $9,796,000, compared to approximately $8,571,000 for the year ended December 31, 2022, an increase of $1,225,000, or 14.3%. The increase in revenue was due to higher interest rates charged on the Company's commercial loans. In 2023, approximately $7,976,000 of its revenue represents interest income on secured, real estate loans that the Company offers to real estate investors, compared to approximately $6,773,000 in 2022, and approximately $1,820,000 represents origination fees on such loans, compared to approximately $1,798,000 in 2022. The loans are principally secured by collateral consisting of real estate and accompanied by personal guarantees from the principals of the borrowers.

Total operating costs and expenses for the year ended December 31, 2023 were approximately $4,353,000, compared to approximately $3,377,000 for the year ended December 31, 2022, an increase of $976,000, or 28.9%. The increase in operating costs and expenses was primarily attributable to an increase in interest expense due to higher interest rates and increases in amounts borrowed relating to the use of the Company's credit line in order to support its ability to increase loan originations, and a special bonus as well as an annual bonus totaling $195,000 to its officers in 2023.

As of December 31, 2023, total shareholders' equity was approximately $42,933,000, compared to approximately $42,864,000 as of December 31, 2022.

On April 11, 2023, the Company's Board of Directors authorized a share buyback program for the repurchase of up to 100,000 of its common shares in the next twelve months. This program does not obligate the Company to purchase any shares and expires on April 10, 2024. As of December 31, 2023, the Company had purchased an aggregate of 54,294 common shares under this repurchase program, at an aggregate cost of approximately $262,000.

Assaf Ran, Chairman of the Board and Chief Executive Officer of the Company, stated, "As real estate investors are adjusting to a high-interest rate environment, liquidity crunches are more frequent. Thus, our challenge for 2023 was to avoid problematic loans and interest collection issues. I can proudly state that I believe we succeeded in meeting the challenge."

"The size of our loan portfolio was approximately the same as the prior year; however, due to the fact that we're low-leveraged, we benefited from the higher interest rates and broke our records of both revenue and net earnings," added Mr. Ran.

About Manhattan Bridge Capital, Inc.

Manhattan Bridge Capital, Inc. offers short-term secured, non-banking loans (sometimes referred to as "hard money'' loans) to real estate investors to fund their acquisition, renovation, rehabilitation or improvement of properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida. We operate the website: https://www.manhattanbridgecapital.com.


MANHATTAN BRIDGE CAPITAL, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
December 31, 2023 and 2022
2023
2022
Assets
Loans receivable$73,048,403 $74,483,463
Interest receivable on loans 1,395,905 1,363,502
Cash
104,222 103,540
Cash - restricted 1,587,773 ---
Other assets 63,636 59,566
Operating lease right-of-use asset, net 207,364 262,222
Deferred financing costs, net 27,583 7,708
Total assets$76,434,886 $76,280,001


Liabilities and Stockholders' Equity
Liabilities:
Line of credit$25,152,338 $24,994,234
Senior secured notes (net of deferred financing costs of $172,069 and $247,155, respectively) 5,827,931 5,752,845
Deferred origination fees 719,019 669,128
Accounts payable and accrued expenses 295,292 289,868
Operating lease liability 220,527 273,485
Dividends payable 1,287,073 1,436,868
Total liabilities 33,502,180 33,416,428
Commitments and contingencies
Stockholders' equity:
Preferred shares - $.01 par value; 5,000,000 shares authorized; none issued --- ---
Common shares - $.001 par value; 25,000,000 shares authorized; 11,757,058 issued; 11,440,651 and 11,494,945 outstanding, respectively 11,757 11,757
Additional paid-in capital 45,548,876 45,535,811
Less: Treasury stock, at cost - 316,407 and 262,113 shares (1,060,606) (798,939)
Accumulated deficit (1,567,321) (1,885,056)
Total stockholders' equity 42,932,706 42,863,573
Total liabilities and stockholders' equity$76,434,886 $76,280,001


MANHATTAN BRIDGE CAPITAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED December 31, 2023 and 2022

2023
2022
Revenue:
Interest income from loans$7,976,232 $6,772,889
Origination fees 1,820,024 1,798,075
Total Revenue 9,796,256 8,570,964
Operating costs and expenses:
Interest and amortization of deferred financing costs 2,525,935 1,822,825
Referral fees 2,153 4,500
General and administrative expenses 1,825,227 1,549,251
Total operating costs and expenses 4,353,315 3,376,576
Income from operations 5,442,941 5,194,388
Other income 33,880 18,000
Income before income tax expense 5,476,821 5,212,388
Income tax expense (650) (650)
Net income$5,476,171 $5,211,738
Basic and diluted net income per common share outstanding:
--Basic$0.48 $0.45
--Diluted

$0.48 $0.45
Weighted average number of common shares outstanding
--Basic 11,469,741 11,494,945
--Diluted 11,469,741 11,494,945


MANHATTAN BRIDGE CAPITAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED December 31, 2023 and 2022

Common StockAdditional
Paid-in

Capital
Treasury StockAccumulated
Deficit
Totals
SharesAmount SharesCost
Balance, January 1, 202211,757,058$11,757$45,522,746262,113$(798,939)$(1,349,322)$43,386,242
Non-cash compensation 13,065 13,065
Dividends paid (4,310,604) (4,310,604)
Dividends declared and payable (1,436,868) (1,436,868)
Net income for the year ended December 31, 2022 5,211,738 5,211,738
Balance, December 31, 202211,757,058 11,757 45,535,811262,113 (798,939) (1,885,056) 42,863,573
Purchase of treasury shares 54,294 (261,667) (261,667)
Non-cash compensation 13,065 13,065
Dividends paid (3,871,363) (3,871,363)
Dividends declared and payable (1,287,073) (1,287,073)
Net income for the year ended December 31, 2023 5,476,171 5,476,171
Balance, December 31, 202311,757,058$11,757$45,548,876316,407$(1,060,606)$(1,567,321)$42,932,706


MANHATTAN BRIDGE CAPITAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED December 31, 2023 and 2022
2023 2022
Cash flows from operating activities:
Net income$5,476,171 $5,211,738
Adjustments to reconcile net income to net cash provided by operating activities -
Amortization of deferred financing costs 93,403 113,736
Depreciation 4,057 2,307
Non-cash compensation expense 13,065 13,065
Adjustment to operating lease right-of-use asset and liability 1,900 4,096
Changes in operating assets and liabilities:
Interest receivable on loans (32,403) (408,059)
Other assets (3,042) 5,742
Accounts payable and accrued expenses 5,424 135,699
Deferred origination fees 49,891 88,667
Net cash provided by operating activities 5,608,466 5,166,991
Cash flows from investing activities:
Issuance of short term loans (56,301,376) (60,915,596)
Collections received from loans 57,736,436 52,147,497
Purchase of fixed assets (5,085) (2,871)
Net cash provided by (used in) investing activities 1,429,975 (8,770,970)


Cash flows from financing activities:
Proceeds from line of credit, net 158,104 9,348,264
Dividends paid (5,308,231) (5,747,472)
Purchase of treasury shares (261,667) ---
Deferred financing costs incurred (38,192) (35,819)
Net cash (used in) provided by financing activities (5,449,986) 3,564,973
Net increase (decrease) in cash and restricted cash 1,588,455 (39,006)
Cash, beginning of year 103,540 142,546
Cash and restricted cash, end of year*$1,691,995 $103,540
Supplemental Disclosure of Cash Flow Information:
Cash paid for taxes during the year$650 $650
Cash paid for interest during the year$2,423,838 $1,581,935
Cash paid for operating leases during the year$64,055 $63,621
Supplemental Schedule of Noncash Financing Activities:
Dividend declared and payable
$1,287,073 $1,436,868

* At December 31, 2023, cash and restricted cash included $1,587,773 of restricted cash.

 
© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.